STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELVN
  4. [Form 3] Enliven Therapeutics, Inc. Initial Statement of Beneficial Ownership

Enliven Therapeutics (ELVN) director discloses stock options in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. director Garland J. Scott filed an initial ownership report showing holdings of fully vested stock options. As of January 7, 2026, he holds options to purchase 13,072 shares of common stock at an exercise price of $24.12 expiring on September 26, 2034, and options to purchase 13,508 shares at an exercise price of $22.47 expiring on February 6, 2035. The filing characterizes these positions as directly owned, and notes that all shares subject to these options are fully vested and exercisable as of the filing date.

Positive

  • None.

Negative

  • None.
Insider Garland J. Scott
Role Director
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
Holdings After Transaction: Stock Option (right to buy) — 13,072 shares (Direct)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Garland J. Scott
(Last) (First) (Middle)
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
(Street)
BOULDER CO 80301
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/07/2026 		3. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 09/26/2034 Common Stock 13,072 $24.12 D
Stock Option (right to buy) (1) 02/06/2035 Common Stock 13,508 $22.47 D
Explanation of Responses:
1. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Remarks:
Exhibit 24.1 - Power of Attorney
/s/ Ben Hohl, by power of attorney 01/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What does Enliven Therapeutics (ELVN) disclose in this Form 3 filing?

This filing reports initial beneficial ownership of Enliven Therapeutics, Inc. securities by director Garland J. Scott, specifically his fully vested stock option holdings.

How many Enliven Therapeutics stock options does Garland J. Scott hold?

He holds stock options over 13,072 shares of common stock and separate stock options over 13,508 shares of common stock.

What are the exercise prices and expiration dates of Garland J. Scott’s ELVN options?

One option grant covers 13,072 shares at an exercise price of $24.12 expiring on September 26, 2034, and another covers 13,508 shares at $22.47 expiring on February 6, 2035.

Are Garland J. Scott’s Enliven Therapeutics options vested and exercisable?

Yes. The footnote states that all of the shares subject to these options are fully vested and exercisable as of the date of the filing.

Is this Form 3 for Enliven Therapeutics reporting a trade or just holdings?

This Form 3 reflects holdings of stock options by Garland J. Scott as of January 7, 2026; it does not report a new purchase or sale transaction.

Does Garland J. Scott hold Enliven Therapeutics options directly or indirectly?

The options are reported as directly owned (D), with no separate entity or indirect ownership nature indicated.